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Purpose. We investigated the clinicopathologic features of early gastric cancer (EGC) patients who have undergone additional
gastrectomy after endoscopic submucosal dissection (ESD) because of their comorbidities. Methods. Eighteen (7.1%) of 252GC
patients were gastrectomized after prior ESD. Reasons for further surgery, preoperative and postoperative problems, and the
clinical outcome were determined. Results. The 18 patients had submucosal EGC and several co-morbidities. Other primary
cancers were observed in 8 (44.4%). Histories of major abdominal operations were observed in 6 (33.3%). Fourteen patients
(77.8%) hoped for endoscopic treatment. Due to additional gastrectomy, residual cancer was suspected in 10, and node metastasis
was suspected in 11. A cancer remnant was histologically observed in one. Node metastasis was detected in 3 (16.7%). Small EGC
was newly detected in 4. Consequently, additional gastrectomy was necessary for the one third. No patient showed GC recurrence.
However, 9 (50%) had new diseases, and 4 (22.2%) died of other diseases. The overall survival after surgery in these patients
with additional gastrectomy was poorer than those with routine gastrectomy for submucosal EGC (P = 0.0087). Conclusions.
Additional gastrectomy was safely performed in EGC patients with co-morbidities. However, some issues, including presence of
node metastasis and other death after surgery, remain.
1.Introduction
Endoscopic treatments, including endoscopic mucosal resec-
tion (EMR) and endoscopic submucosal dissection (ESD),
for early gastric cancer (EGC) have markedly progressed and
are widely accepted [1–3]. EMR can be safely performed
for EGC conditioned by diﬀerentiated mucosal EGC smaller
than 20mm in diameter [4], and the general indications
were proposed by the Japanese Gastric Cancer Association.
Recently, ESD is frequently used for the treatment of EGC
because ESD has the advantage of curability on achieving
successful en-block resection [1–3]. Furthermore, extended
indicationsofEMR/ESDforEGChavebeenclinicopatholog-
ically investigated [5–8]. The expanded criteria of EMR/ESD
for EGC are still controversial [9], and the expanded criteria
need to be conﬁrmed yet. Most mucosal EGC showed low-
level lymph node metastasis while approximately 15–20%
of submucosal EGC showed node metastasis [10]. There are
casesthatunderwentadditionalgastrectomyafterEMR/ESD,
because cancer invades the submucosal layer of the stomach
with/without lymphovascular invasion histopathologically
detected in specimens obtained by EMR/ESD. Regarding
criteria for EGC treatment, patients sometimes hope for
endoscopic treatment, as it is less invasive compared to
surgery. Haruma et al. [11] reported that endoscopic therapy
in patients who are inoperable or have a high surgical
risk appears eﬀective. There have recently been reports
regarding additional treatments, including gastrectomy, after
incomplete EMR/ESD [12, 13]. Patients with gastrectomy
after prior EMR/ESD may have several problems regarding
thesurgicalmanagementandlong-termoutcome.Especially,
the clinicopathologic issues, excluding the histopathologic
features of gastric cancer, in gastrectomized patients after
prior ESD have not yet been investigated.
We retrospectively investigated the clinicopathologic
issuesconcerninggastrectomizedpatientsafterESDforEGC,
and the reasons for ESD and further surgery for EGC, and
pre- and postoperative problems were determined from a
surgical viewpoint.2 International Journal of Surgical Oncology
2. Patientsand Methods
2.1. Patients. We retrospectively analyzed our database of
all GC patients who underwent gastrectomy. A total of 252
patientswithGCwerenewlydiagnosedandsurgicallytreated
between 2004 and 2008 at Shinshu University Hospital.
Eighteen patients (15 men and 3 women, 7.1%: Group A)
were additionally gastrecomized after ESD for EGC. Sixty-
four patients (49 men and 15 women, 25.4%: Group B)
were routinely and electively gastrectomized for EGC with
submucosal invasion.
2.2. Clinicopathologic Issues. The following parameters were
investigated: (1) problems before treatments, (a) comorbidi-
ties, (b) multiple cancers of other organs, and (c) history of
major abdominal surgery and invasive treatment for other
diseases; (2) reason for treatment of EGC, (a) reason for
receiving ESD, and (b) reason for additional gastrectomy
(pathologic ﬁndings of ESD); (3) pathologic ﬁndings after
additional gastrectomy; (4) postoperative complications; (5)
clinical outcome after additional gastrectomy. Finally the
clinicopathologic features in Group A were compared with
those of Group B.
2.3. Endoscopic Treatment. ESD for EGC was performed by
several gastrointestinal endoscopists in Shinshu University
HospitalandotherhospitalsinNaganoPrefecture.Onehun-
dred and ﬁfty-three patients received endoscopic treatments
in the same period, and 15 (9.8%) of the 153 patients with
additional gastrectomy received prior endoscopic treatments
at our hospital. The remaining 3 visited from other hospitals
for endoscopic treatment of EGC in our hospital. ESD
for EGC was carried out employing a few methods using
hook and ﬂex knives or an insulation-tipped diathermic
knife. Usually, mucosal EGC was indicated for ESD and en-
block removal. The removed tissues were formalin ﬁxed and
paraﬃn embedded. The obtained sections were histopatho-
logicallyexaminedandwereroutinelyevaluatedaccordingto
the Japanese Classiﬁcation of Gastric Carcinoma established
by the Japanese Gastric Cancer Association [14].
2.4. Gastrectomy after ESD. When the histopathologic ﬁnd-
ings after ESD showed submucosal invasion with/without
lymphatic or venous invasions, additional gastrectomy was
considered. Gastrectomy with regional node dissection for
EGC with/without prior ESD was performed employing
an open or laparoscopy-assisted approach. When EGC was
located in the lower and middle thirds of the stomach, distal
gastrectomy was performed. When EGC was located in the
upper third of the stomach, total or proximal gastrectomy
was performed. Regional nodes were routinely dissected
using the procedure of D1 (with no. 7) or (with no. 7, 8a,
and 11p) in patients with EGC. In advanced GC, D2-node
dissection was usually performed. These resected specimens
and lymph nodes were examined according to the routine
histopathologic procedures for diagnosis and staging. The
clinicopathologic features of GC were described according
to the Japanese Classiﬁcation of Gastric Carcinoma [14]. All
18 patients with additional gastrectomy were performed D1-
lymphadenectomy: 14 with node dissection surrounding left
gastric arteries and 4 with additional dissection of the nodes
surrounding the common hepatic and splenic and celiac
arteries.
2.5. Clinical Outcome after Surgery. For 5 years after
surgery, these patients were followed in the outpatient
clinic of Shinshu University Hospital in order to check for
recurrence/metastasis of the tumors by esophagogastroduo-
denoscopyeveryyearandcomputedtomography(CT)ofthe
abdomen and chest every 6 months and/or annually. Death
caused by recurrence/metastasis of GC or by other diseases
after surgery was investigated.
2.6. Statistical Analysis. Data are shown as the prevalence, or
meanandordinaldatawerecomparedbytheMann-Whitney
U and Chi-square or Fisher’s exact probability test. Five-year
survival rates after surgery were calculated employing the
Kaplan-Meier method. P<0.05 was considered signiﬁcant.
3. Results
3.1. Problems before Treatments
Comorbidities. All 18 patients had one or more comorbidi-
ties before treatments for EGC (Table 1). Additionally, two
of 4 patients with diabetes mellitus had not yet been treated,
and insulin treatment was started for surgery. One with
chronic obstructive pulmonary disease and one with idio-
pathic interstitial pneumonia routinely underwent home-
oxygenic treatment. Two patients with dermatomyositis were
treated with predonisolone long term.
Multiple Cancers in Other Organs. Other primary can-
cers were observed in 8 patients (44.4%: Table 2). Nine
antecedent cancers in other organs were observed in 7
patients, while one synchronous cancer was observed in the
liver. In these patients, 6 tumors had undergone surgical
treatment.
History of Major Surgery and Invasive Treatment. Histories
of major abdominal operations were observed in 6 patients
(33.3%). Gastrectomy had been carried out for previous
EGC in one patient. Colectomy for advanced colon cancer
hadbeenconductedin2patients.Oophorectomyforovarian
cancer and benign ovarian tumor had been performed
in one each. Hysterectomy for uterine cancer had been
performed in one patient. Hepatectomy for hepatocellular
carcinoma and the extirpation of retroperitoneal liposar-
coma had been performed in one. A history of invasive
treatment/operation for other disorders was observed in 3
patients (16.7%): surgical clipping of cerebral aneurysm,
coronary artery bypass grafting, or percutaneous coronary
intervention for ischemic heart disease. These invasive treat-
ments with/without surgery were performed in 9 patients
(50.0%).
3.2. Reason for Treatment of EGC
Reason for Receiving ESD. Regarding the patients’ opinions,
14 (77.8%) of the 18 patients hoped for ESD treatmentInternational Journal of Surgical Oncology 3
Table 1: Preoperative comorbidities in patients with additional
gastrectomy.
Comorbidities No. of cases
Cardiovascular diseases 10 (55.6%)
Hypertension 8
Angina pectoris 2
Complete atrioventricular block 1
Pericarditis induced by radiotherapy 1
Cerebral diseases 5 (27.8%)
Infarction 4
Hemorrhage 1
Diabetes mellitus 4 (22.2%)
Pulmonary diseases 4 (22.2%)
Chronic obstructive pulmonary disease 2
Interstitial pneumonia 2
Liver cirrhosis 2 (11.1%)
Dermatomyositis 2 (11.1%)
Idiopathic thrombocytopenic purpura 1 (5.6%)
Amyloidosis 1 (5.6%)
for EGC. They gave the following reasons: their advanced
age, comorbidities, history of abdominal surgery, and social
convenience. Regarding the doctors’ opinions, EGC was
suspected as submucosal cancer, but diagnostic treatment
was conducted in 4 patients (22.2%) by ESD.
Reason for Additional Gastrectomy (Pathologic Findings of
ESD). Twenty-three EGC were removed by ESD in the
18 patients; double lesions patients were removed in 5
patients (27.8%). Cut-end margins of 11 lesions in 10
patients (55.6%) were positive: the positive lateral margin
in 3 patients (16.7%) and the positive vertical margin in 8
patients (44.4%). In one patient, both margins were positive.
Submucosal invasion was demonstrated in 19 lesions of the
18 patients. Submucosal invasion less than 500µmf r o m
the muscularis mucosa (sm1) was shown in 5 lesions of
4 patients (22.2%), and submucosal invasion deeper than
500µm from the muscularis mucosa (sm2) in 14 lesions of
14 patients (77.8%). Histological vessel invasions, including
lymphatic and/or venous invasions, were shown in 11
lesions: 2 lesions with sm1 and 9 lesions with sm2. Based
on the histopathologic ﬁndings of EGC specimens after
ESD, residual cancer was suspected in 10 patients, and node
metastasiswassuspectedin11patientsbecauseofpresenceof
histologic lymphatic and/or venous invasion. The remaining
2 showed a regional node swelling (over 10mm in diameter)
on abdominal CT in the followup after ESD. Finally, the 18
patients underwent additional gastrectomy.
3.3. Pathologic Findings after Surgery. In primary lesions,
cancer remnant was observed in only one patient, while no
remnant was observed in 17 patients (94.4%). New cancer
was detected in the resected stomach after gastrectomy in
4 patients (22.2%); 2 of the 4 patients had a third cancer.
Theselesionsweremucosalandlessthan10mmindiameter;
majority of them shows 2–4mm in size. Node metastasis
was observed in 3 patients (16.7%). Two cases pathologically
showed a metastatic node, and one had 4 metastatic node.
The 2 cases with preoperatively suspected node metastasis
on CT revealed no metastasis histologically. In addition,
Helicobacter pylori was observed in 17 (94.4%), but the
presence was same between the patients with single and
multiple gastric cancer in Group A.
3.4. Postoperative Complications. Postoperative complica-
tions were observed in 9 patients (50.0%) in Group A. Liver
dysfunction was observed in 3 patients; one of them showed
massive ascites, approximately 1,000-mL drainage, every day
aftersurgery.Infectionofthecentralcatheterwasobservedin
2 patients with total gastrectomy. Postoperative delirium was
observed in 2 patients. Other postoperative complications
wereacutepancreatitis,pericarditiswithheartfailure,angina
pectoris, and atrial ﬁbrillation with tachycardia. These
complications were conservatively treated, and consequently
improved. In Group B, no case with anastomotic leakage
was also observed. There was no diﬀerence of postoperative
morbidity between Group A and Group B. No postoperative
mortality was observed. In addition, there was no diﬀerence
in operative blood loss and operating time between the two
groups (Table 3).
3.5. Clinical Outcome after Surgery. In the followup, there
was no case of additional gastrectomy with cancer recur-
rence/metastasis. New disorders after surgery were observed
in 9 patients (50.0%). Mental/neurological diseases, includ-
ing depression and dementia, were observed in 4 patients
over 75 years old. Other primary cancers were subsequently
observed in 2 patients (11.1%): hepatocellular carcinoma 26
months after and lung cancer 50 months later. Cancer of the
gastric remnant was newly detected 36 months after distal
gastrectomy. Death due to other diseases was observed in 4
patients (22.2%) without the recurrence of EGC: respiratory
failure due to amyloidosis, hepatic failure due to cirrhosis,
metastatic lung cancer detected after gastrectomy, and the
recurrence of esophageal cancer treated by chemoradiother-
apy before ESD.
A signiﬁcant diﬀerence between Group A and Group B
was observed in the age, tumor size, histologic diﬀerentia-
tion, preoperative complications, surgical risk, and death by
other diseases (Table 3). New disorders after surgery were
frequently observed in Group A than Group B although
this was not statistically signiﬁcant. No case with gastric
cancer recurrence was observed in Group A as well as
Group B. Group A showed a less favorable outcome after
surgery in terms of overall survival than Group B (P =
0.0087). However, the cancer survival rate after additional
gastrectomy was the same in the two groups.
4. Discussion
There are several clinicopathologic issues in patients with
submucosal cancer treated by additional gastrectomy after
ESD for EGC. Two major points regarding diagnostic
and therapeutic issues in these patients with additional4 International Journal of Surgical Oncology
Table 2: Multiple cancers in other organs.
Other primary cancers No. of cases Treatment
Metachronous cancer before ESD 7
Squamous cell carcinoma/esophagus 2 ESD (1), CRT (1)
Adenocarcinoma/duodenum 1 ESD
Adenocarcinoma/colon 2 Surgery
Hepatocellular carcinoma/liver 1 Surgery
Adenocarcinoma/ovary 1 Surgery
Squamous cell carcinoma/uterus 1 Surgery
Liposarcoma/retroperitoneum 1 Surgery
Synchronous cancer 1
Hepatocellular carcinoma/liver 1 Surgery
ESD, endoscopic submucosal dissection; CRT, chemoradiotherapy.
gastrectomy were considered. One is a problem regarding
EGC and metastasis, including incomplete resection by
ESD, the presence of node metastasis before ESD, and the
oversight of small EGC and metachronous cancer after
ESD. The other is a problem regarding patients involving
the surgical risk, other primary cancers, and new disorders
after gastrectomy. On consideration of these issues, it is
important that additional gastrectomy is employed based on
the histopathologic ﬁndings after ESD.
There was only one case with a cancer remnant on
the removed stomach although 9 showed positive lateral
and/or vertical margins after ESD. Piecemeal resections of
EGC by EMR have been reported to be associated with a
high risk of local recurrence [1], and ESD for EGC has
the advantage of being associated with a lower frequency
of recurrence than EMR [2]. Furthermore, Yokoi et al. [15]
reported that ESD facilitates the curative resection of locally
recurrent EGC. In the present study, 94.4% of the cases with
additional gastrectomy had no cancer remnant. This ﬁnding
may be explained by burn degeneration at the cut-end of
EGC treated by ESD. Tanabe et al. [16] reported that the
mean width of burning degeneration at the cut ends of EGC
treated by ESD was 1,203µm. Goto et al. [17] reported that
preceding ESD for EGC had no negative inﬂuence on the
prognosis when additional gastrectomy was performed, and
i tm a yb ep e r m i s s i b l et or e m o v es o m eE G Cb yE S Da saﬁ r s t
step to prevent unnecessary gastrectomy. Therefore, cases
without local recurrence of EGC may undergo the omission
of additional gastrectomy when no node metastasis can be
deﬁnitely shown.
Mutual features in the cases with node metastasis
detected after additional gastrectomy were considered as
follows: (1) a protruding type tumor, (2) over 25mm in
tumor size, (3) moderately diﬀerentiated type, (4) sm2, (5)
positive lymphatic invasion, but (6) no cancer remnant after
ESD. Furthermore, the 3 had preoperative comorbidities and
a surgical history of laparotomy. Gotoda et al. [5]r e p o r t e d
that 18.6% of submucosal EGC showed node metastasis
histopathologically, while 91% of surgically treated EGC did
not have node metastasis. Oda et al. [13] reported that
6.3% of noncurative patients with a possible risk of node
metastasis after EMR/ESD for EGC showed regional node
metastasis after gastrectomy. The present cases had to receive
gastrectomy initially, because their histopathologic ﬁndings
after ESD were considered to be associated with a high risk
of node metastasis in EGC. However, they desired not to
undergo surgery because of their advanced age, presence of
physicalandsocialcomplications,andhistoryoflaparotomy.
It is hard to detect regional nodes with metastasis employing
abdominal ultrasonography, endoscopic ultrasonography,
CT, and conventional magnetic resonance imaging [18].
A new modality is necessary for an accurate diagnosis of
node metastasis in patients with EGC before EMR/ESD and
surgery.Additionalgastrectomybasedonthehistopathologic
ﬁndings after ESD is unnecessary in two thirds of the
present cases without cancer remnants or node metastases,
while the fact that additional gastrectomy is necessary in
one third of the patients may be important. From the
ﬁndings of the three cases with node metastasis detected
after additional gastrectomy, we suggested that additional
gastrectomy should be performed in EGC patients with
co-morbidity showing over 25mm in tumor size, sm2-
invasion, and lymphatic invasion. However, it is possible
that additional gastrectomy after ESD is avoided in the other
patients, when no small cancer is detected endoscopically.
Regarding multiple gastric cancer after EMR/ESD, in the
present study, 33.3% of the cases synchronously showed
multiple EGC. Four lesions, detected after additional gas-
trectomy, were missed prior to ESD. Probably, endoscopists
might overlook these lesions because of their small size.
Nasu et al. [19] reported the characteristics of metachronous
and synchronous EGC on initial EMR. Takenaka et al.
[20] reported metachronous cancers of the gastric remnant
after distal gastrectomy and the utility of ESD for EGC of
the gastric remnant. Although EGC newly detected after
additional gastrectomy was mucosal and small cancer, these
lesions may have the potential to become metachronous
cancer after ESD in the future.
Most of the patients undergoing additional gastrec-
tomy hoped for treatment of EGC by ESD as a less-
invasive procedure because they had several underlying
diseases/preoperativecomorbiditiesandsurgicalhistoriesfor
other diseases. They were elderly and had a higher surgical
risk in gastrectomy after ESD than routine gastrectomy forInternational Journal of Surgical Oncology 5
Table 3: A Comparison of the clinicopathologic features of gastrectomized patients with and without ESD.
Variable With ESD (n = 18) Without ESD (n = 64) P value
Age (mean ± SD: year-old) 72.5 ±6.36 7 .5 ±10.8 0.029
Gender 0.39
Men 15 49
Women 3 15
Location 0.19
Upper 9 19
Middle 6 22
Lower 3 23
Tumor size (mean ± SD: mm 25.1 ±12.13 5 .1 ±18.40 . 0 4
Gross type 0.08
Protruding/elevated 11 21
Flat 0 2
Depressed/excavated 7 41
Histologic diﬀerentiation 0.012
Well/moderately 18 48
Poorly/signet ring cell 0 16
Depth of invasion 0.71
sm 1 4 17
sm 2 14 47
Node metastasis 0.63
Positive 3 11
Negative 15 53
Lymphatic invasion 0.52
Positive 8 34
Negative 10 30
Venous invasion 0.057
Positive 5 34
Negative 13 30
Hepatic metastasis 0.78
Positive 0 1
Negative 18 63
Tumor number 0.19
Solitary 12 52
Double or more 6 12
Preoperative comorbidities <0.001
Positive 18 34
Negative 0 30
History of major abdominal surgery 0.4
Positive 6 15
Negative 12 49
History of gastrectomy 0.7
Positive 1 4
Negative 17 60
History of major extra-abdominal surgery 0.38
Positive 3 7
Negative 15 57
Other primary cancer 0.3
Positive 8 20
Negative 10 44
Surgical risk 0.012
Positive 18 48
Negative 0 166 International Journal of Surgical Oncology
Table 3: Continued.
Variable With ESD (n = 18) Without ESD (n = 64) P value
Operating time (mean ± SD: min) 312.5 ±74.2 314.4 ±82.50 . 7 7
Total gastrectomy 327.2 ±46.93 4 .6 ±65.00 . 5 7
Distal gastrectomy 304.5 ±86.7 293.8 ±86.60 . 6 9
Operative blood loss (mean ± SD: mL) 190.6 ±134.4 222.0 ±148.00 . 4 3
Total gastrectomy 206.7 ±110.2 242.6 ±166.40 . 7 9
Distal gastrectomy 181.8 ±150.3 208.9 ±135.80 . 1 3
Postoperative complications 0.14
Positive 9 20
Negative 9 44
New disorders in followup 0.074
Positive 9 19
Negative 9 45
Death by other diseases 0.019
Positive 4 2
Negative 14 62
SD, standard deviation.
submucosal cancer. Furthermore, the nonelderly patients
under 70 years old with additional gastrectomy also had
several preoperative comorbidities. Hirasaki et al. [21]
reported that elderly patients over 75 years old treated by
ESD for EGC frequently had underlying diseases, but there
were no diﬀerences in complications after ESD and the
complete resection rate. Kakushima et al. [22]r e p o r t e d
that the complete resection rate in ESD for EGC and
the complication rate after ESD in elderly patients were
not signiﬁcantly diﬀerent from those of younger patients.
Because the number of elderly EGC patients with/without
underlying diseases and surgical risk has been steadily
increasing worldwide, we should pay attention to these
EGC patients, treated by ESD and/or additional gastrectomy,
regarding the clinicopathologic issues of age and comorbidi-
ties. Postoperative complications were frequently observed
in the gastrectomized patients after ESD compared to those
treated with routine gastrectomy; however, no mortality was
observed in this series. No data from large-scale studies was
found in postoperative morbidity and mortality comparing
between EGC patients receiving additional and routine
gastrectomy.
The disease free-survival rate after additional gastrec-
tomy in patients with incomplete ESD for EGC was not
worse [17], similar to the present study. No data were found
for other primary cancers and new disorders, including
mental/neurological disorders, in a long-term followup of
EGC patients treated by additional gastrectomy after ESD.
Approximately 1.5–5.4% of patients with subsequent cancer
in other organs developing metachronously were detected
after EGC treatment [23–25]. The number of patients with
o t h e rs u b s e q u e n tc a n c e r sa f t e rs u r g e r yf o rE G Cm a yn o tb e
so high, but a high frequency (16.7%) of other subsequent
cancers was observed in the present study. Furthermore, no
data were found regarding new disorders after additional
gastrectomy for EGC, although the clinicopathologic studies
of ESD in elderly patients with EGC were identiﬁed [21, 22].
The fact that the present cases with additional gastrectomy
frequently had comorbidities/underlying diseases may aﬀect
the capacity to discover new disorders after additional
gastrectomy. From these ﬁndings, it was considered that
overall survival of cases with additional gastrectomy was
poorer than in those receiving routine gastrectomy for
submucosal EGC.
5. Conclusion
EGC patients with a number of comorbidities, including
a surgical history and multiple cancers in other organs,
may hope for less-invasive treatment by ESD. Consequently,
additional gastrectomy may be recommended in one third,
and we should consider several issues, including surgical
problems as well as the complete resection of cancer
and node metastasis before/after additional gastrectomy.
Additional gastrectomy is safely performed in EGC patients
with several comorbidities. It is possible that additional
gastrectomy may be avoided in the other patients with
comorbidities, when another small EGC may not be detected
endoscopically.Regardingthefollowup,anissuethatsomeof
these patients died of other diseases remains. Furthermore,
new modalities for diagnosis of lymph node metastasis may
need for omission of additional gastrectomy.
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